Cosentyx And Entresto Keep Powering Novartis As Firm Mulls Sandoz Sale

Sales Forecasts Lifted For Top Two Earners

26 Oct 2021

CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.

As Novartis AG launches a strategic review of its ailing generics business Sandoz, the Swiss major has hiked peak sales targets for its two stellar commercial successes, Cosentyx and Entresto.

Unveiling Novartis's third quarter financials to journalists this morning, CEO Vas Narasimhan noted that sales of the cardiovascular therapy Entresto (sacubitril/valsartan) soared by 44% at constant currencies to $924m, "driven by demand as essential first-choice therapy for heart failure patients," according to the company. In the US, sales have been boosted by approval from the Food and Drug Administration in February of an expanded indication for heart failure for preserved ejection fraction (HFpEF) to add to Entresto's initial approval for heart failure with reduced ejection fraction (HFrEF)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

06 May 2025

• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Lilly’s Ricks Urges Trump To Pick Tax Incentives Over Tariffs

02 May 2025

• By Alaric DeArment

On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.

Transient FY26 For Syngene But Momentum In China +1 Projects

02 May 2025

• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.